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 INTRODUCTION 
Worldwide, hypertension represents one of the most 
common complications of pregnancy. Hypertension 
disorder continue to occur globally, complicating 5-20% 
of pregnancies. Its incidence varies from 2 to 8% of 
pregnancies in developed countries reaching 10% or 
more in developing countries. 1, 2   Hypertension in 
pregnancy is defined as systolic blood pressure (sBP) ≥ 
140 mmHg and/or diastolic blood pressure (dBP) ≥ 90 
mmHg, or by ↑ in sBP ≥ 30 mmHg, or in dBP ≥15 
mmHg from preconception or first trimester blood 
pressure confirmed by two measuring 6 hours apart. 3 
It is associated with high rates of perinatal morbidity and 
mortality and is the third most common cause of 
maternal death worldwide. Pre-eclampsia decreases 
utero-placental perfusion, which puts the foetus at high 
risk for problems such as preterm birth and perinatal 
mortality. It may also lead to maternal hypertension and 
multisystemic organ dysfunction and damage, including 
eclampsia. 4, 5 
A number of drugs in various combinations are generally 
used for effective long –term management of 
hypertension in pregnancy. There is need to survey the 
pattern of usage of antihypertensives drugs, to see if the 
current usage is rational, effective and tolerated and in 
concordance with current guidelines for treatment of 
hypertension.6 The greatest challenge in treating 
hypertension in pregnancy is to reduce the blood 
pressure to assure the safety of mother and at same time 
not to compromise uteroplacental perfusion or cause 
harmful effects on the foetus.10The ideal therapy of 
hypertension in pregnancy should be potent, rapidly 
acting and without any adverse maternal or foetal effect.7 
The present study aims to investigate the drug utilization 
pattern of antihypertensive drugs in pregnancy induced 
hypertension. 
METHODS 
A retrospective observational study was conducted in the 
Department of Obstetrics & Gynaecology, College of 
Medicine & JNM Hospital, Kalyani after taking 
permission from the Institutional Ethics Committee. The 
Case record sheets of the patients diagnosed for 
pregnancy induced hypertension or gestational 
hypertension admitted to the obstetrics ward during the 
period July – December 2013 were reviewed. 
The information regarding drugs prescribed, number of 
drugs, dosage, frequency, duration, whether generic 
names used were recorded and from this the core 
indicators like prescribing indicators and complementary 
indicators were evaluated. 
Prescribing indicators 
8
 
a) Average number of drugs per patient was calculated 
by dividing the total number of different drug products 
prescribed by the number of patients surveyed.  
b) Percentage of drugs prescribed by generic name was 
determined by dividing the number of drugs prescribed 
by generic name by the total number of drugs prescribed, 
multiplied by 100.  
c) Percentage of drugs prescribed from essential drug list 
was determined by dividing the number of products 
prescribed from essential drug list of the hospital by the 
total number of drugs prescribed, multiplied by 100.  
Complementary Indicators  
a) Effect of the drug on the foetus (Low birth Weight, 
Foetal distree, IUGR, death) 
b) category and safety of prescribed drugs. 
Definition of risk factors 
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These definitions are those used by the United States 
food and Drug Administration (FDA). 9 
Category A: 
Controlled studies in women fail to demonstrate a risk to 
the foetus in the 1st trimester (and there is no evidence of 
a risk in later trimesters), and the possibility of foetal 
harm remains remote. 
Category B: 
Either animal-reproduction studies have not 
demonstrated a foetal risk but there are no controlled 
studies in pregnant women or animal-reproduction 
studies have shown an adverse effect (other than a 
decrease in fertility) that was not confirmed in controlled 
studies in women in the 1st trimester (and there is no 
evidence of a risk in later trimesters). 
Category C: 
Either studies in animals have revealed adverse effects 
on the foetus (teratogenic or embryocidal or other) and 
there are no controlled studies in women and animals are 
not available. Drugs should be given only if the potential 
benefits justify the potential risk to the foetus. 
Category D: 
There is positive evidence of human foetal risk, but the 
benefits from use in pregnant women may be acceptable 
despite the risk (e.g. if the drug is needed in a life-
threatening situation or for a serious disease for which 
safer drugs cannot be used or are ineffective). 
Category X: 
Studies in animals or human beings have demonstrated 
foetal abnormalities or there is evidence of foetal risk 
based on human experience or both, and the risk of the 
use drug in pregnant women clearly outweighs any 
possible benefits. The drug is contraindicated in women 
who are, or may become pregnant. 
RESULTS 
A total of 154 prescriptions were collected. Among these 
patients, a higher number, 55.84 % belonged to stage II 
hypertension (B.P . ≥ 160/ ≥ 100) before administration 
of drugs (Table 3). Neonatal outcome of these 
pregnancies were noted which showed low birth weight 
in 18.83% cases, followed by foetal distress in 3.24% 
cases. (Table 4) 
Out of 154 patients, 123 (i.e, 79.87%) received a single 
antihypertensive drug while 27 (i.e,17.53 %) received 
two antihypertensive drugs and 4 patients (2.59%) 
received three drugs.(Table 5) 
Methyl dopa was the most common antihypertensive 
drug used as monotherapy in 54 (i.e, 35.06% cases) , 
followed by Labetalol in 32 (i.e, 20.77%) cases. 
Combination of Methyl dopa and Labetalol was the most 
common multidrug antihypertensive regimen used in 
7.79% cases. 
Average number of antihypertensives per prescription 
was found to be 1.22. A total of 83.76% prescriptions 
were found in generic name. 
 
Table 1: Demographic distribution of the patients 
Age Groups Number of patients Percentage 
18-20 19 12.33 
21-25 84 54.55 
26-30 36 23.37 
31-35 15 9.74 
 
Table 2: Gravidity wise distribution of patients 
Gravida Number of patients Percentage 
Primi 79 51.29 
Second 48 31.16 
Third 21 13.63 
Fourth 6 3.89 
 
Table 3: Blood pressure range of patients before administration of drugs 
B.P. Classification Systolic/ Diastolic B.P. Number of patients Percentage 
Hypertension stage I 140-159/ 90-99 68 44.16 
Hypertension stage II ≥ 160/ ≥ 100 86 55.84 
 
Table 4: Neonatal outcomes 
Neonatal Outcome Number of patients Percentage 
Low Birth Weight 29 18.83 
Foetal distress 5 3.24 
IUGR 3 1.94 
Death 2 1.29 
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Table 5: Number of antihypertensive drugs 
Number of Drugs Number of patients Percentage 
Single drug 123 79.87 
Two drugs 27 17.53 
Three drugs 4 2.59 
 
Table 6: Antihypertensive drug/ combination used 
Name of Drug/s Number of patients Percentage Risk category 
Methyl dopa 54 35.06 B 
Labetalol 32 20.77 C 
Nifedipine 26 16.88 C 
Amlodipine 6 3.89 C 
Magnesium sulfate 5 3.24 A 
Methyl dopa + Labetalol 12 7.79 B+ C 
Methyl dopa + Nifedipine 8 5.19 B+ C 
Labetalol + Nifedipine 7 4.54 C+ C 
Methyl dopa + Labetalol + Nifedipine 4 2.59 B+ C+ C 
 
Table 7: Drug use indicators 
Core Indicator Value 
Average number of drugs per prescription 4.2 
Average number of antihypertensives per prescription 1.22 
Prescriptions by generic name  
 
83.76% 
On Essential Drug List 64.28% 
  
Facility Indicators  
Availability of Essential Drug List Yes 
Availability of Key drugs 100% 
 
 
DISCUSSION 
In our study, as described earlier, 79.87 % patients 
admitted with Pregnancy induced hypertension, received 
monotherapy antihypertensive regimen which is similar 
to an earlier study in Govt hospital by Ashna S Pandya et 
al. which showed 75.96% patients received a single 
antihypertensive drug.  However,  another study by 
Naveen Kumar T et al showed much less (46.94%) 
percentage of patients receiving monotherapy in 
pregnancy induced hypertension.
10,11
 
Methyl dopa was found to be the most common 
antihypertensive prescribed, followed by Labetalol. 
Similarly, in earlier studies mentioned above, 
Methyldopa was most commonly prescribed, however in 
those studies Nifedipine was the second most commonly 
used drug. 
Rational drug use in pregnancy requires balancing of 
benefits and the potential risks associated with the use of 
drugs. The majority of drugs used in this study were 
from Category B and C. Magnesium Sulfate, belonging 
to category A(safest) was used in less number of 
patients. However, in contrast to earlier study by Naveen 
Kumar T et al., drugs belonging to categories with higher 
risk (category D) like Atenolol or Telmisartan were not 
found in our present study which shows better adherence 
to guidelines. 
The most common neonatal outcome was low birth 
weight baby. The co-relation of the effect of PIH on 
foetal weight should be evaluated by further studies. The 
incidence of IUGR, premature babies and foetal distress 
were also noticed but it cannot be co-related to PIH or 
drugs used in this study. 
CONCLUSION  
Hypertension in pregnancy is one of the most common 
disorders encountered in pregnancy . Methyldopa was 
found to be the commonest prescribed antihypertensive 
in monotherapy and combination, as it is safe during 
pregnancy. The incidence of Low birth weight babies 
was high which may be due to either effect of maternal 
hypertension or drugs which should be evaluated by 
further studies. None of the prescribed drugs were from 
teratogenic category D and X. 
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